COVID-19与肾移植的系统综述
该系统综述检索2020年4月和8月的英文及中文文献,纳入至少20例确诊SARS-CoV-2感染的肾移植受者且报告完整结局的研究。共20项研究,以描述性为主,来自法国、意大利、西班牙、土耳其、英国和美国。早期报告显示住院肾移植受者死亡风险高,但研究易受时期效应影响,需谨慎解读。
要点
- 住院肾移植受者感染COVID-19早期报告死亡风险高。
- 移植后60天内感染COVID-19的患者死亡率达46%(基于西班牙早期数据)。
- 急性肾损伤常见,多数患者停用霉酚酸。
核心结论
- 住院肾移植受者感染COVID-19在早期报告中死亡风险高,但需谨慎解读,因研究易受时期效应影响。
- 中期和长期结局仍不确定,值得仔细研究。
研究设计与样本
- 系统综述,检索2020年4月和8月多个资源的英文和中文文献。
- 纳入至少20例确诊SARS-CoV-2感染的肾移植受者且报告完整结局的研究,共20项研究。
- 研究以描述性为主,来自法国、意大利、西班牙、土耳其、英国和美国。
主要发现
- 已发表研究的死亡率可变。
- 基于西班牙早期数据,移植后60天内发生COVID-19的患者中46%死亡。
- 急性肾损伤常见,多数患者停用霉酚酸。
- 质量评估显示在对照组选择和额外因素控制方面存在局限。
临床怎么用
- 临床应关注住院肾移植受者感染COVID-19的高死亡风险。
- 注意急性肾损伤的常见性,并考虑多数患者停用霉酚酸的做法。
- 需谨慎解读早期数据,因研究易受时期效应影响。
局限性
- 研究以描述性为主,质量评估显示在对照组选择和额外因素控制方面存在局限。
- 研究易受时期效应影响。
- 中期和长期结局仍不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Kidney transplant recipients are at increased susceptibility to many viral infections leading to justifiable anxiety about the effects of coronavirus disease 2019 (COVID-19). METHODS: We performed literature searches from multiple resources in April and August 2020 for relevant English and Chinese literature. Abstracts were screened, followed by full-text review with data extraction of reports that included at least 20 kidney transplant recipients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and completed outcomes. RESULTS: Twenty studies had sufficient data, which we have summarized. Studies were predominantly descriptive and came from France, Italy, Spain, Turkey, United Kingdom, and United States. Quality assessment demonstrated limitations in selection of comparison groups and controlling for additional factors. Mortality rates from published studies were variable. Based on early data early from Spain, 46% of patients who developed COVID-19 within 60 days of transplantation died. Acute kidney injury was common, and mycophenolate was discontinued in most patients. CONCLUSION: Given the rapid global spread of COVID-19, reliable evidence is needed to inform public health policies. Hospitalized kidney transplant recipients with COVID-19 are at a high risk of death in early reports but interpretation of these data requires caution, as studies were susceptible to period effects. Reassuringly, the quality of observational data is improving. Detailed and comprehensive data collection through linked registries will be necessary to conduct accurate analyses of risk factors for adverse outcomes, not least given the risks of stopping imunosuppression. This report highlights the early mortality excess in transplant recipients but medium- and longer-term outcomes remain uncertain and merit careful investigation.
引用
- Mahalingasivam V, Craik A, Tomlinson LA, et al. A Systematic Review of COVID-19 and Kidney Transplantation. Kidney Int Rep. 2020. PMID: 33163708. doi:10.1016/j.ekir.2020.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。